Overview

• Corsera says its preclinical RNA interference drug is designed to block PCSK9 and angiotensinogen in a single annual dose to cut lifelong cardiovascular risk.
• The company expects to start human testing by the end of 2025, positioning the program for primary prevention rather than treatment of established disease.
• Co-founders John Maraganore and Clive Meanwell will serve as co-CEOs, drawing on prior work that led to Novartis’s Leqvio.
• An AI tool called Clotho (Klotho) Health is trained on datasets including the UK Biobank to flag people likely to benefit, with deployment options under evaluation.
• Corsera reports roughly $50 million in founder and insider funding, is raising additional capital, and says it will pursue population-scale reach with accessible pricing.